Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation.

Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Abstract Text:

Maneesh Jain,Ganesh Venkatraman,Surinder K Batra,

In contrast to the overwhelming success of radiolabeled antibodies in treating hematologic malignancies, only modest success has been achieved in the radioimmunotherapy of solid tumors. One of the major limitations in successful application of radioimmunotherapy is the large molecular size of the intact immunoglobulin that results in prolonged serum half-life and poor tumor penetration and uptake. With the advent of antibody engineering, small molecular weight antibody fragments exhibiting improved pharmacokinetics and tumor penetration have been generated. However, their clinical application has been limited by suboptimal tumor uptake and short tumor residence time. There is a greater realization that optimization of the molecular size of the antibodies alone is not sufficient for clinical success of radioimmunotherapy. In addition to their size, radiolabeled antibodies encounter other impediments before reaching their target antigens expressed on the cell surface of solid tumors. Some of the barriers include poor blood flow in large tumors, permeability of vascular endothelium, elevated interstitial fluid pressure of tumor stroma, and heterogeneous antigen expression. Recent research has considerably improved our understanding and appreciation of these forces, and the new wave of optimization strategies involves the use of biological modifiers to modulate the impediments posed by solid tumors. In combination with radiolabeled antibodies, various agents are being used to improve the tumor blood flow, enhance vascular permeability, lower tumor interstitial fluid pressure by modulating stromal cells and extracellular matrix components, up-regulate the expression of target antigens, and improve the penetration and retention of the radiopharmaceuticals. This review outlines ongoing research efforts involving biological modifiers to optimize the uptake and efficacy of radiolabeled antibodies for the treatment of solid tumors.

Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Publishing Authors By Initials

M Jain,G Venkatraman,SK Batra,

For similar therapeutics: biological therapy: immunotherapy: radioimmunotherapy research abstracts see: therapeutics: biological therapy: immunotherapy: radioimmunotherapy research

PUBMED ID PMID:

MEDLINE DATE:

Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Journal Published:

PUBLICATION TYPE: Review

Journal: Clinical cancer research : an official journal of

VOLUME: 13

Page Numbers: 1374-82

Journal Abbreviation: Clin. Cancer Res.

ISSN: 1078-0432

DAY: 19

MONTH: 02

YEAR: 2007

Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Information

Number of References: 97

LANGUAGE: eng

NlmUniqueID: 9502500

Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Keywords Mesh Terms:

KEYWORDS: Radioimmunotherapy

MESH TERMS: methods

Chemical & Substance for Abstract: Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Information

Substance Name: Antibodies

Registry Number: 0

Grant and Affiliation Information for Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation.

AFFILIATION: Department of Biochemistry and Molecular Biology, Department of Pathology and Microbiology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska 68198-5870, USA.

Country: United States

AGENCY: United States NCI

GRANT: R01 CA78590

ACRONYM: CA

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation Related Publications

• Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).
• Alternate splicing at the 3'-end of the human pancreatic tumor-associated mucin MUC4 cDNA.
• Cigarette smoke-induced differential expression of the genes involved in exocrine function of the rat pancreas.
• Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
• Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies.
• Development of a real-time PCR assay for the diagnosis of scrub typhus cases in India and evidence of the prevalence of new genotype of O. tsutsugamushi.
• Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy.
• Engineering antibodies for clinical applications.
• Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis.
• Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans.
• Generation and characterization of murine monoclonal antibodies to recombinant 26-kDa periplasmic protein of Brucella abortus.
• Human MUC4 mucin cDNA and its variants in pancreatic carcinoma.
• Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells.
• IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response.
• Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis.
• Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies.
• MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms.
• MUC4 mucin expression in human pancreatic tumours is affected by organ environment: the possible role of TGFbeta2.
• MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins.
• MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications.
• Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance.
• Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy.
• Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation.
• Purification and characterization of a human pancreatic adenocarcinoma mucin.
• Retinoic acid-dependent transforming growth factor-beta 2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor-alpha signaling pathway.
• Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma.
• Simultaneous direct detection of toxigenic and non-toxigenic Vibrio cholerae from rectal swabs and environmental samples by sandwich ELISA.
• Spotted fevers & typhus fever in Tamil Nadu.
• Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies.
• [Hydroxy(tosyloxy)iodo]benzene mediated alpha-azidation of ketones.